Srikumar Sahasranaman

Srikumar Sahasranaman has an extensive work experience in the field of clinical pharmacology. Srikumar is currently serving as the SVP of Quantitative Clinical Pharmacology at Prelude Therapeutics since April 2023. Prior to this, they were a member of the Board of Directors at IQ Consortium from January 2021 to March 2023. From January 2017 to March 2023, they held the position of Vice President of Clinical Pharmacology at BeiGene. Srikumar worked at Genentech as a Group Leader/Senior Scientist in Clinical Pharmacology from May 2010 to December 2016. Before that, they were an Expert Pharmacokineticist at Novartis from September 2006 to May 2010. From August 2004 to September 2006, they worked as a Senior Research Investigator at Sanofi-aventis. Srikumar started their career as an intern at the FDA from June 2003 to August 2003.

Srikumar Sahasranaman completed their Bachelor of Pharmacy with Honors degree at the Birla Institute of Technology and Science in Pilani from 1993 to 1997. Srikumar then pursued their Master of Science in Pharmacy at the National University of Singapore from 1998 to 2000. Following this, they went on to earn their Ph.D. in Pharmaceutical Sciences from the University of Florida, where they studied from 2000 to 2004.